-

Company Profile for bioAffinity Technologies, Inc.

--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology are conducted in bioAffinity Technologies’ laboratories at the University of Texas San Antonio (UTSA). The Company’s platform technology is being developed to diagnose, monitor and treat many cancers.

Company:

bioAffinity Technologies, Inc.

 

 

Headquarters Address:

22211 W I-10, Suite 1206

 

San Antonio, TX 78257

 

 

Main Telephone:

5054009747

 

 

Website:

www.bioaffinitytech.com

 

 

Type of Organization:

Private

 

 

Industry:

Biotechnology

 

 

Key Executives:

CEO: Maria Zannes

 

 

Public Relations

 

Contact:

Julie Anne Overton

Phone:

5055770918

Email:

jaoverton@mac.com

 

bioAffinity Technologies, Inc.

NASDAQ:BIAF
Details
Headquarters: San Antonio, TX
CEO: Maria Zannes
Employees: 52
Organization: PUB

Release Versions

More News From bioAffinity Technologies, Inc.

bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable

SAN ANTONIO, Texas--(BUSINESS WIRE)--bioAffinity Technologies will present case studies at NLCRT in which CyPath® Lung identified Stage 1A lung cancer in high-risk patients....

bioAffinity Technologies Reports Third Quarter 2025 Financial Results

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies reports Q3 2025 financial results, achieves 86% increase in CyPath® Lung testing revenue....

bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies announced the volume of CyPath® Lung tests processed in October increased by 111% over the 2025 monthly average....
Back to Newsroom